118 related articles for article (PubMed ID: 37922573)
21. BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer.
Kim S; Rimm D; Carter D; Khan A; Parisot N; Franco MA; Bale A; Haffty BG
Breast J; 2003; 9(3):167-74. PubMed ID: 12752624
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Factors for Luminal B-like Breast Cancer.
Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
[TBL] [Abstract][Full Text] [Related]
23. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer.
Huang NS; Chi YY; Xue JY; Liu MY; Huang S; Mo M; Zhou SL; Wu J
Oncotarget; 2016 Jun; 7(25):37957-37965. PubMed ID: 27191888
[TBL] [Abstract][Full Text] [Related]
26. Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive Breast Cancer.
Sato K; Akimoto K
Clin Breast Cancer; 2017 Jun; 17(3):e135-e142. PubMed ID: 27986439
[TBL] [Abstract][Full Text] [Related]
27. Deciphering the nexus between the tumor immune microenvironment and DNA methylation in subgrouping estrogen receptor-positive breast cancer.
Chen XQ; Zhang F; Xiao FH; Peng Y
Breast Cancer; 2021 Nov; 28(6):1252-1260. PubMed ID: 33966175
[TBL] [Abstract][Full Text] [Related]
28. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.
Arora A; Parvathaneni S; Aleskandarany MA; Agarwal D; Ali R; Abdel-Fatah T; Green AR; Ball GR; Rakha EA; Ellis IO; Sharma S; Madhusudan S
Mol Cancer Ther; 2017 Jan; 16(1):239-250. PubMed ID: 27837030
[TBL] [Abstract][Full Text] [Related]
30. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
31. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
Bardou VJ; Arpino G; Elledge RM; Osborne CK; Clark GM
J Clin Oncol; 2003 May; 21(10):1973-9. PubMed ID: 12743151
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen therapy benefit predictive signature combining with prognostic signature in surgical-only ER-positive breast cancer.
Lv F; Jin WH; Zhang XL; Wang ZR; Sun AJ
J Cell Physiol; 2019 Jul; 234(7):11140-11148. PubMed ID: 30537139
[TBL] [Abstract][Full Text] [Related]
33. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
34. ENDORSE: a prognostic model for endocrine therapy in estrogen-receptor-positive breast cancers.
Nath A; Cohen AL; Bild AH
Mol Syst Biol; 2022 Jun; 18(6):e10558. PubMed ID: 35671075
[TBL] [Abstract][Full Text] [Related]
35. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
[TBL] [Abstract][Full Text] [Related]
36. Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma.
Serrero G; Hawkins DM; Yue B; Ioffe O; Bejarano P; Phillips JT; Head JF; Elliott RL; Tkaczuk KR; Godwin AK; Weaver J; Kim WE
Breast Cancer Res; 2012 Feb; 14(1):R26. PubMed ID: 22316048
[TBL] [Abstract][Full Text] [Related]
37. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
38. Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up.
Markićević M; Džodić R; Buta M; Kanjer K; Mandušić V; Nešković-Konstantinović Z; Nikolić-Vukosavljević D
Int J Med Sci; 2014; 11(7):663-73. PubMed ID: 24843314
[TBL] [Abstract][Full Text] [Related]
39. Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression.
Kocatürk B; Tieken C; Vreeken D; Ünlü B; Engels CC; de Kruijf EM; Kuppen PJ; Reitsma PH; Bogdanov VY; Versteeg HH
J Thromb Haemost; 2015 Sep; 13(9):1683-93. PubMed ID: 26179105
[TBL] [Abstract][Full Text] [Related]
40. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
